Inclusion Criteria:

- Histologically or cytologically confirmed metastatic melanoma

- Stage IV or unresectable stage III disease

- Measurable disease, defined as ≥ 1 lesion that can be accurately measured in ≥ 1
dimension (longest diameter to be recorded) as ≥ 20 mm by conventional techniques or
as ≥ 10 mm by spiral computed tomography (CT) scan

- No known brain metastases

- Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2 OR Karnofsky PS
60-100%

- Life expectancy > 12 weeks

- White blood cell (WBC) ≥ 3,000/mcL

- Absolute neutrophil count (ANC) ≥ 1,500/mcL

- Platelet count ≥ 100,000/mcL

- Hemoglobin ≥ 9 g/dL

- Total bilirubin normal

- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 times upper
limit of normal

- Creatinine normal OR creatinine clearance ≥ 60 mL/min

- Proteinuria ≤ 1+ by dipstick OR 24-hour urine protein ≤ 1 g

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception prior to study until completion of
study treatment

- No history of allergic reactions attributed to compounds of similar chemical or
biologic composition to AZD0530

- No QTc prolongation (defined as a QTc interval ≥ 480 msecs) or other significant
electrocardiogram (ECG) abnormalities

- No poorly controlled hypertension (e.g., systolic blood pressure [BP] of ≥ 140 mm Hg
or diastolic BP of ≥ 90 mm Hg)

- No condition (e.g., gastrointestinal tract disease resulting in an inability to take
oral medication or a requirement for IV alimentation), prior surgical procedures
affecting absorption, or active peptic ulcer disease that impairs the ability to
swallow AZD0530 tablets

- No intercurrent cardiac dysfunction including, but not limited to, any of the
following:

- Symptomatic congestive heart failure

- Unstable angina pectoris

- Cardiac arrhythmia

- No recent history of ischemic heart disease including myocardial infarction

- No uncontrolled intercurrent illness including, but not limited to, ongoing or active
infection or psychiatric illness/social situations that would limit compliance with
study requirements

- No other malignancy within the past 5 years, except definitively treated, localized,
nonmelanoma skin cancer or low-grade cervical neoplasm

- At least 4 weeks since prior and no more than one prior treatment regimen for
advanced disease

- No prior kinase inhibitor with activity against Src kinases for metastatic melanoma

- More than 4 weeks since prior luteinizing hormone-releasing hormone agonists

- No concurrent combination antiretroviral therapy for human immunodeficiency virus
(HIV)-positive patients

- No concurrent prohibited cytochrome P450 3A4 (CYP3A4)-active agents or substances

- Prohibited drugs should be discontinued 7 days prior to the administration of
the first dose of AZD0530 and for 7 days following discontinuation of AZD0530

- No other concurrent investigational agents or commercial therapies